<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: ⁹⁰Y-labeled anti-CD66b monoclonal antibody clone BW 250/183 was developed for treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the study was the analysis of CD66 expression in lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> to expand the potential of anti-CD66-based therapy </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Bone marrow samples from 260 patients were examined for the expression of CD66 on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 104 B-<z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo> (B-CLL), 28 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), 22 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (FCL), 15 marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>), 12 lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (LPL), 13 diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), 4 T-non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (T-NHL), 3 B-NHL not otherwise specified (B-NHL NOS), 3 B <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>), and in 56 <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo> (MM) by flow cytometry </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Positive (≥ 20%) expression of CD66abce clone Kat4c was detected in 76% of B-CLL and 76.8% of MM </plain></SENT>
<SENT sid="4" pm="."><plain>The highest number of CD66abce-positive samples was in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and LPL (96.4% of 28 and 91.7% of 12 patients, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of CD66b clone BW 250/183 was examined in 114 of 260 samples </plain></SENT>
<SENT sid="6" pm="."><plain>Positive expression was detected in 23.3% of B-CLL (6/35), 17.1% of MM (7/30), and 21.4% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (3/14) samples </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The expression of CD66b compared to CD66abce was lower in <z:hpo ids='HP_0000001'>all</z:hpo> measured samples </plain></SENT>
<SENT sid="8" pm="."><plain>Use of radiolabeled anti-CD66b antibody for the treatment of <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> appears to have limited preclinical substantiation </plain></SENT>
</text></document>